Prediagnosis biomarkers of insulin-like growth factor-1, insulin, and interleukin-6 dysregulation and multiple myeloma risk in the Multiple Myeloma Cohort Consortium.

Insulin-like growth factor-1 (IGF-1), insulin, and IL-6 are dysregulated in multiple myeloma pathogenesis and may also contribute to multiple myeloma etiology. To examine their etiologic role, we prospectively analyzed concentrations of serologic markers in 493 multiple myeloma cases and 978 controls from 8 cohorts in the Multiple Myeloma Cohort Consortium. We computed odds ratios (ORs) and 95% confidence intervals (CIs) for multiple myeloma per 1-SD increase in biomarker concentration using conditional logistic regression. We examined heterogeneity by time since blood collection (≤ 3, 4- ≤ 6, and > 6 years) in stratified models. Fasting IGF binding protein-1 concentration was associated with multiple myeloma risk within 3 years (OR, 95% CI per 1-SD increase: 2.3, 1.4-3.8, P = .001) and soluble IL-6 receptor level was associated within 6 years after blood draw (OR (≤ 3 years), 95% CI, 1.4, 1.1-1.9, P = .01; OR(4- ≤ 6 years), 95% CI, 1.4, 1.1-1.7, P = .002). No biomarker was associated with longer-term multiple myeloma risk (ie, > 6 years). Interactions with time were statistically significant (IGF binding protein-1, P-heterogeneity = .0016; sIL6R, P-heterogeneity = .016). The time-restricted associations probably reflect the bioactivity of tumor and microenvironment cells in transformation from monoclonal gammopathy of undetermined significance or smoldering multiple myeloma to clinically manifest multiple myeloma.

[1]  L. Murphy,et al.  Free insulin-like growth factor I (IGF-I) in healthy subjects: relationship with IGF-binding proteins and insulin sensitivity. , 1997, The Journal of clinical endocrinology and metabolism.

[2]  J. Gohagan,et al.  Etiologic and early marker studies in the prostate, lung, colorectal and ovarian (PLCO) cancer screening trial. , 2000, Controlled clinical trials.

[3]  B Rosner,et al.  Determination of blood pressure percentiles in normal-weight children: some methodological issues. , 2008, American journal of epidemiology.

[4]  A. Greenberg,et al.  Obesity and the role of adipose tissue in inflammation and metabolism. , 2006, The American journal of clinical nutrition.

[5]  B. Barlogie,et al.  Monoclonal gammopathy of undetermined significance (MGUS) and smoldering (asymptomatic) multiple myeloma: IMWG consensus perspectives risk factors for progression and guidelines for monitoring and management , 2010, Leukemia.

[6]  O. Stephens,et al.  An intermediate-risk multiple myeloma subgroup is defined by sIL-6r: levels synergistically increase with incidence of SNP rs2228145 and 1q21 amplification. , 2012, Blood.

[7]  T. Therneau,et al.  Increased risk of monoclonal gammopathy in first-degree relatives of patients with multiple myeloma or monoclonal gammopathy of undetermined significance. , 2008, Blood.

[8]  S. Rudikoff,et al.  Insulin-like growth factor I is a dual effector of multiple myeloma cell growth. , 2000, Blood.

[9]  P. Heinrich,et al.  Interleukin‐6 is the major regulator of acute phase protein synthesis in adult human hepatocytes , 1989, FEBS letters.

[10]  T. Rème,et al.  Growth factors in multiple myeloma: a comprehensive analysis of their expression in tumor cells and bone marrow environment using Affymetrix microarrays , 2010, BMC Cancer.

[11]  B. Klein,et al.  Increased and highly stable levels of functional soluble interleukin‐6 receptor in sera of patients with monoclonal gammopathy , 1993, European journal of immunology.

[12]  F. Berrino,et al.  Fasting glucose is a risk factor for breast cancer: a prospective study. , 2002, Cancer epidemiology, biomarkers & prevention : a publication of the American Association for Cancer Research, cosponsored by the American Society of Preventive Oncology.

[13]  S. Larsson,et al.  Body mass index and risk of multiple myeloma: A meta‐analysis , 2007, International journal of cancer.

[14]  E. Rimm,et al.  Prospective study of alcohol consumption and risk of coronary disease in men , 1991, The Lancet.

[15]  J. Scheller,et al.  Interleukin‐6 biology is coordinated by membrane‐bound and soluble receptors: role in inflammation and cancer , 2006, Journal of leukocyte biology.

[16]  N. Cook,et al.  Blood Pressure Differences by Ethnic Group Among United States Children and Adolescents , 2009, Hypertension.

[17]  R. Bataille,et al.  CD221 (IGF-1R) is aberrantly expressed in multiple myeloma, in relation to disease severity. , 2005, Haematologica.

[18]  S. Rudikoff,et al.  Insulinlike growth factor-I signaling in multiple myeloma: downstream elements, functional correlates, and pathway cross-talk. , 2002, Blood.

[19]  JoAnn E. Manson,et al.  Design of the Women's Health Initiative clinical trial and observational study. The Women's Health Initiative Study Group. , 1998, Controlled clinical trials.

[20]  D O Stram,et al.  Singapore Chinese Health Study: Development, Validation, and Calibration of the Quantitative Food Frequency Questionnaire , 2001, Nutrition and cancer.

[21]  R. Kyle,et al.  Advances in the diagnosis, classification, risk stratification, and management of monoclonal gammopathy of undetermined significance: implications for recategorizing disease entities in the presence of evolving scientific evidence. , 2010, Mayo Clinic proceedings.

[22]  G. Hallmans,et al.  Temporal reliability of cytokines and growth factors in EDTA plasma , 2010, BMC Research Notes.

[23]  H. Asaoku,et al.  Autocrine generation and requirement of BSF-2/IL-6 for human multiple myelomas , 1988, Nature.

[24]  R. Hayes,et al.  Monoclonal gammopathy of undetermined significance (MGUS) consistently precedes multiple myeloma: a prospective study. , 2009, Blood.

[25]  T. Therneau,et al.  Long-term follow-up of 241 patients with monoclonal gammopathy of undetermined significance: the original Mayo Clinic series 25 years later. , 2004, Mayo Clinic proceedings.

[26]  G A Colditz,et al.  Alcohol, height, and adiposity in relation to estrogen and prolactin levels in postmenopausal women. , 1995, Journal of the National Cancer Institute.

[27]  M. Stampfer,et al.  A prospective study of plasma C-peptide and colorectal cancer risk in men. , 2004, Journal of the National Cancer Institute.

[28]  D. English,et al.  The Melbourne Collaborative Cohort Study. , 2002, IARC scientific publications.

[29]  M. Kearney,et al.  IGF-dependent and IGF-independent actions of IGF-binding protein-1 and -2: implications for metabolic homeostasis , 2009, Trends in Endocrinology & Metabolism.

[30]  Woon-Puay Koh,et al.  Angiotensin I-converting enzyme (ACE) gene polymorphism and breast cancer risk among Chinese women in Singapore. , 2003, Cancer research.

[31]  K. Vanderkerken,et al.  The microenvironment and molecular biology of the multiple myeloma tumor. , 2011, Advances in cancer research.

[32]  M. Pollak.  Insulin-like growth factor physiology and cancer risk. , 2000, European journal of cancer.

[33]  T. Therneau,et al.  Serum free light chain ratio is an independent risk factor for progression in monoclonal gammopathy of undetermined significance. , 2005, Blood.

[34]  H. Yki-Järvinen,et al.  Portal insulin concentrations rather than insulin sensitivity regulate serum sex hormone-binding globulin and insulin-like growth factor binding protein 1 in vivo. , 1995, The Journal of clinical endocrinology and metabolism.

[35]  G. Colditz,et al.  Body Mass Index, Physical Activity, and Risk of Multiple Myeloma , 2007, Cancer Epidemiology Biomarkers & Prevention.

[36]  N. Cook,et al.  Baseline characteristics of participants in the Women's Health Study. , 2000, Journal of women's health & gender-based medicine.

[37]  M. Jourdan,et al.  Insulin is a potent myeloma cell growth factor through insulin/IGF-1 hybrid receptor activation , 2010, Leukemia.

[38]  T. Whiteside.  Cytokine measurements and interpretation of cytokine assays in human disease , 1994, Journal of Clinical Immunology.

[39]  S. Rudikoff,et al.  Insulin-like growth factor I induces migration and invasion of human multiple myeloma cells. , 2004, Blood.

[40]  E. Capoluongo,et al.  Reduction of serum IGF-I levels in patients affected with Monoclonal Gammopathies of undetermined significance or Multiple Myeloma. Comparison with bFGF, VEGF and K-ras gene mutation , 2009, Journal of experimental & clinical cancer research : CR.

[41]  E. Barrett-Connor,et al.  Epidemiology of insulin-like growth factor-I in elderly men and women. The Rancho Bernardo Study. , 1997, American journal of epidemiology.

[42]  J. Fraumeni,et al.  Obesity is associated with an increased risk of monoclonal gammopathy of undetermined significance among black and white women. , 2009, Blood.

[43]  W. Koh,et al.  Plasma carotenoids and risk of acute myocardial infarction in the Singapore Chinese Health Study. , 2011, Nutrition, metabolism, and cardiovascular diseases : NMCD.

[44]  Graham A. Colditz,et al.  The Nurses' Health Study: lifestyle and health among women , 2005, Nature Reviews Cancer.

[45]  T. Hideshima,et al.  Novel therapies in MM: from the aspect of preclinical studies , 2011, International journal of hematology.

[46]  T. Hirano.  Interleukin 6 (IL-6) and its receptor: their role in plasma cell neoplasias. , 1991, International journal of cell cloning.

[47]  D. Dunger,et al.  Association between Insulin-Like Growth Factor-I , 2004, Cancer Epidemiology Biomarkers & Prevention.